Outcomes with single agent LIPO-DOX in platinum-resistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital experience

Background: Single pegylated liposomal doxorubicin (PLD) is commonly used as a salvage treatment in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma (PPA) with a satisfactory outcome. However, the data for second generation PLD administered in this setti...

Full description

Saved in:
Bibliographic Details
Main Authors: Suprasert P., Manopunya M., Cheewakriangkrai C.
Format: Article
Language:English
Published: Asian Pacific Organization for Cancer Prevention 2014
Online Access:http://www.scopus.com/inward/record.url?eid=2-s2.0-84896820972&partnerID=40&md5=09179a068b0dbcb9af6131afa102ac4c
http://www.ncbi.nlm.nih.gov/pubmed/24606432
http://cmuir.cmu.ac.th/handle/6653943832/1702
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
Language: English
id th-cmuir.6653943832-1702
record_format dspace
spelling th-cmuir.6653943832-17022014-08-30T01:59:57Z Outcomes with single agent LIPO-DOX in platinum-resistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital experience Suprasert P. Manopunya M. Cheewakriangkrai C. Background: Single pegylated liposomal doxorubicin (PLD) is commonly used as a salvage treatment in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma (PPA) with a satisfactory outcome. However, the data for second generation PLD administered in this setting are still limited. We conducted a retrospective study to evaluate the outcome of patients who received single-agent second generation PLD (LIPO-DOX) after the development of clinical platinum resistance. The study period was between March 2008 and March 2013. LIPO-DOX was administered intravenously 40 mg/m2 every 28 days until disease progression, but for not more than six cycles. The response rate was evaluated using the Gynecologic Cancer Intergroup (GCIG) criteria while the toxicity was evaluated according to WHO criteria. Twenty-nine patients met the inclusion criteria in the study period with an overall response rate of 13.8%. The median progression free survival and overall survival were three and eleven months, respectively. With the total of 96 cycles of chemotherapy, the patients developed grades 3 and 4 hematologic toxicity as follows: anemia, 0%, leukopenia, 9.6%, neutropenia, 32.3% and thrombocytopenia, 0%. In conclusion, the single agent second generation PLD demonstrated modest efficacy in patients with platinum-resistant ovarian cancer, fallopian tube cancer and PPA without serious toxicity. 2014-08-30T01:59:57Z 2014-08-30T01:59:57Z 2014 Article 15137368 10.7314/APJCP.2014.15.3.1145 http://www.scopus.com/inward/record.url?eid=2-s2.0-84896820972&partnerID=40&md5=09179a068b0dbcb9af6131afa102ac4c http://www.ncbi.nlm.nih.gov/pubmed/24606432 http://cmuir.cmu.ac.th/handle/6653943832/1702 English Asian Pacific Organization for Cancer Prevention
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
language English
description Background: Single pegylated liposomal doxorubicin (PLD) is commonly used as a salvage treatment in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma (PPA) with a satisfactory outcome. However, the data for second generation PLD administered in this setting are still limited. We conducted a retrospective study to evaluate the outcome of patients who received single-agent second generation PLD (LIPO-DOX) after the development of clinical platinum resistance. The study period was between March 2008 and March 2013. LIPO-DOX was administered intravenously 40 mg/m2 every 28 days until disease progression, but for not more than six cycles. The response rate was evaluated using the Gynecologic Cancer Intergroup (GCIG) criteria while the toxicity was evaluated according to WHO criteria. Twenty-nine patients met the inclusion criteria in the study period with an overall response rate of 13.8%. The median progression free survival and overall survival were three and eleven months, respectively. With the total of 96 cycles of chemotherapy, the patients developed grades 3 and 4 hematologic toxicity as follows: anemia, 0%, leukopenia, 9.6%, neutropenia, 32.3% and thrombocytopenia, 0%. In conclusion, the single agent second generation PLD demonstrated modest efficacy in patients with platinum-resistant ovarian cancer, fallopian tube cancer and PPA without serious toxicity.
format Article
author Suprasert P.
Manopunya M.
Cheewakriangkrai C.
spellingShingle Suprasert P.
Manopunya M.
Cheewakriangkrai C.
Outcomes with single agent LIPO-DOX in platinum-resistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital experience
author_facet Suprasert P.
Manopunya M.
Cheewakriangkrai C.
author_sort Suprasert P.
title Outcomes with single agent LIPO-DOX in platinum-resistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital experience
title_short Outcomes with single agent LIPO-DOX in platinum-resistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital experience
title_full Outcomes with single agent LIPO-DOX in platinum-resistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital experience
title_fullStr Outcomes with single agent LIPO-DOX in platinum-resistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital experience
title_full_unstemmed Outcomes with single agent LIPO-DOX in platinum-resistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital experience
title_sort outcomes with single agent lipo-dox in platinum-resistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - chiang mai university hospital experience
publisher Asian Pacific Organization for Cancer Prevention
publishDate 2014
url http://www.scopus.com/inward/record.url?eid=2-s2.0-84896820972&partnerID=40&md5=09179a068b0dbcb9af6131afa102ac4c
http://www.ncbi.nlm.nih.gov/pubmed/24606432
http://cmuir.cmu.ac.th/handle/6653943832/1702
_version_ 1681419719754645504